ENT Department, Katholisches Klinikum, Rudolf-Virchow-Str.7, 56073, Koblenz, Germany,
Eur Arch Otorhinolaryngol. 2014 Jun;271(6):1491-6. doi: 10.1007/s00405-013-2647-1. Epub 2013 Aug 6.
The objectives of this study were (1) to assess the protective role of NMDA antagonists against the ototoxic effects of aminoglycosides, (2) to provide any possible evidence between ototoxicity due to aminoglycosides and excitotoxicity. An animal experiment was conducted. Twenty-eight, 3-month-old female New Zealand rabbits, weighing 1,000-1,500 g, were studied prospectively for 28 days after intramuscular administration of amikacin (15 mg/kg/day divided into two equal doses) for 14 days. Twenty-one rabbits were categorized into three equal treatment groups and seven animals received no medication and served as the control group. The animals of A, B and C groups were injected, intramuscularly, with amikacin 15 mg/kg/day, divided into two equal doses every day for 14 days. Animals of group A received in parallel memantine (per os) and those of group B received p.o. the same volume of placebo solution. The rabbits of the third group (group C) received on the 15th day and every 2 days for the next 2 weeks, until the day 28, memantine of the same quantity as the members of group A. Differences in DPOAE amplitudes, and therefore in cochlear activity, between group A and group B were revealed. DPOAE amplitudes of group B were further reduced compared to the respective amplitudes in rabbits of group A. No improvement was observed in DPOAE measurements performed after the discontinuation of injections. The findings in group C should be examined separately. The measurements showed apparent reversal ototoxic effects in four of the animals. The development of aminoglycoside otoprotective strategies is a primary goal in ototoxicity research. The administration of NMDA antagonists has been shown to prevent, at least to some extent, toxic damage to hair cells in guinea pigs, treated with aminoglycoside antibiotics.
(1)评估 NMDA 拮抗剂对氨基糖苷类耳毒性的保护作用;(2)提供氨基糖苷类耳毒性与兴奋性毒性之间的任何可能的联系。开展了一项动物实验。28 只 3 月龄雌性新西兰兔,体重 1000-1500g,肌肉注射阿米卡星(15mg/kg/天,分为 2 等份)14 天,前瞻性研究 28 天。21 只兔子分为 3 组,每组 7 只,未接受药物治疗作为对照组。A、B、C 组动物分别肌肉注射阿米卡星 15mg/kg/天,每天 2 等份,连续 14 天。A 组动物同时口服美金刚,B 组动物口服等量安慰剂溶液。C 组动物第 15 天及第 15 天后每隔 2 天给予与 A 组相同剂量的美金刚,直至第 28 天。结果显示 A、B 两组间的 DPOAE 幅度(耳蜗功能)存在差异。与 A 组相比,B 组 DPOAE 幅度进一步降低。停药后 DPOAE 测量未见改善。C 组的结果应单独检查。C 组的 4 只动物的测量值显示出明显的逆转耳毒性作用。开发氨基糖苷类耳保护策略是耳毒性研究的主要目标。NMDA 拮抗剂的给药已被证明可预防,至少在一定程度上,豚鼠接受氨基糖苷类抗生素治疗后毛细胞的毒性损伤。